Showing results (41-50 of 99) with videos related to

Sort By:
Pageof 10
Plos One|October 1, 2014
Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasionMarie Lundholm, Mona Schröder, Olga Nagaeva, et al.
The Lancet. Oncology|March 17, 2009
Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trialPer Fransson, Jo-Asmund Lund, Jan-Erik Damber, et al.
The Journal of Urology|July 13, 2010
Do perceptions of adverse events differ between patients and physicians? Findings from a randomized, controlled trial of radical treatment for prostate cancerE Andreas Svaboe Steinsvik, Sophie D Fosså, Karol Axcrona, et al.
International Journal of Radiation Oncology, Biology, Physics|February 1, 2020
Erectile Dysfunction and Absorbed Dose to Penile Base Structures in a Randomized Trial Comparing Ultrahypofractionated and Conventionally Fractionated Radiation Therapy for Prostate CancerElisabeth Rasmusson, Adalsteinn Gunnlaugsson, Elinore Wieslander, et al.
International Journal of Radiation Oncology, Biology, Physics|July 6, 2010
Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trialArne Solberg, Olav A Haugen, Trond Viset, et al.
Plos One|November 19, 2013
Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variantsEmma Jernberg, Elin Thysell, Erik Bovinder Ylitalo, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 13, 2025
Routinely collected health data on 10-year genitourinary and gastrointestinal morbidity after ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer in the randomised, non-inferiority, phase 3 trial HYPO-RT-PCAstrid E Persson, Elisabeth Kjellén, Hans Garmo, et al.
Plos One|May 10, 2011
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survivalEmma Hörnberg, Erik Bovinder Ylitalo, Sead Crnalic, et al.
The Prostate|April 6, 2021
Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivoMalin Hagberg Thulin, Jorma Määttä, Anna Linder, et al.
European Urology|March 31, 2016
Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7Sophie D Fosså, Fredrik Wiklund, Olbjørn Klepp, et al.
Pageof 10